Quin­tiles­IMS an­a­lysts fore­cast a wave of new drug ap­provals by '22, dom­i­nat­ed by can­cer and or­phan ther­a­pies

To hear an­a­lysts at the Quin­tiles­IMS In­sti­tute tell it, 2016’s sud­den plunge in new drug ap­provals was an aber­ra­tion that won’t be re­peat­ed any­time over the next five years. In their new, an­nu­al drug spend­ing re­port, the an­a­lysts at this group de­ter­mined that the in­dus­try pipeline is brim­ming full and like­ly to spew out 40 to 45 new drug ap­provals every year from this year through 2022, re­turn­ing to a lev­el set in 2014 and 2015.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.